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ARE HEPATIC ADENOMAS PREMALIGNANT?
ABSTRACT
Foster, J.H. and Berman, M.M. (1994) The malignant transformation of liver cell
adenomas. Arch Surg., 129: 717-717.
Objective: To investigate clinical experience with the apparent malignant transforma-
tion of benign liver cell adenomas.
Design: Retrospective review of personal experience and literature.
Setting: University hospital and affiliated community hospitals.
Patients: All patients diagnosed with liver cell adenomas over a 30-year period.
Interventions: Liver resection and/or tumor biopsy.
Main Outcome Measures: Gender, age, drug associations, alpha-fetoprotein levels,
response to treatment, and survival.
Results: Thirteen patients from personal experience and 26 patients from the reports of
others had liver cell adenomas that were not resected. Five of these patients subse-
quently developed hepatocellular carcinoma.
Conclusions: Malignant transformation of a liver cell adenoma is a rare phenomenon,
but it does occur. Alphafetoprotein levels may be more helpful in diagnosis than
expected from previous reports. Solitary benign adenomas should be resected whenever
possible. Patients with diffuse multiple tumors should be observed closely over a long
period. Arch Surg. 1994; 129:712-717
KEY WORDS: Hepatic adenoma hepatocellular carcinoma
PAPER DISCUSSION
Doctors James Foster and Martin Berman, both re-
spected and recognized authorities ofhepatic tumors in
their respective fields, have examined the reported
clinical evidence for the malignant transformation of
59
liver cell adenomas (LCA). In brief, they culled 39
patients with LCAs that were not resected or were in-
completely resected from their own experience or from
other reports. Five patients developed hepatocellular
carcinoma after the diagnosis ofLCA. These findings,
at face value, suggest that nearly 13% of patients with60 HPB INTERNATIONAL
unresected LCA risk malignant degeneration. How-
ever, Foster and Berman interestingly conclude that
malignant transformation is "a rare phenomenon".
Although their conclusionmay seem incongruous with
the absolute value of their finding, their analysis is
convincingly expounded.
This original article examined several reputed asso-
ciations between LCA and malignant transformation:
number of LCAs, contraceptive steroid use, alpha
fetoprotein levels, and the diagnostic interval between
confirmation of benign and malignant hepatoceilular
histology. None of these factors were predicative of
malignant transformation. Cessation ofsteroid use did
not abort the risk ofmalignant tranformation. Alpha-
fetoprotein level was not a consistent marker ofmalig-
nancy. Patients with multiple LCAs were too few to
assess and diagnostic intervals between the LCA and
HCC were marginal (3.5 years or less) in two patients.
Despite illusions to the reputed frequency ofthe malig-
nant potential for LCAs, only five cases were substan-
tive enough to even support the premise. Furthermore,
Foster and Berman emphasized that the natural his-
tory ofLCA isunknown. Ofthe 22 patients with incom-
pletely or unresected LCAs proven histologically who
had reported follow-up, LCAs decreased in size in
nearly 2/3 while the remainder were unchanged. The
factors relevant to the size decrease ofLCAs were inde-
terminant. Neither rupture nor cancer were recognized
and few patients developed any symptoms. The natural
history of LCAs in this very selected review was re-
markably benign. Clearly, the coincidence ofLCA and
HCC is rare.
Have the authors provided us with enough evidence
to support malignant transformation of this specific
hepatic pathology? What basic objective evidence is
required for malignant transformation of a benign
denoma? First, histologic confirmation (not cytologic)
ofboth benign and malignant liver cell pathologymust
be established according to accepted pathologic stand-
ards. Second, a diagnostic interval of such duration
must exist to temporally permit the cellular and
gross neoplastic transformation. Finally, imaging
data should confirm a single site of hepatic origin.
Clearly, histologic evidence is essential and independ-
ent pathologic coraboration is optimal. Cytologic in-
terpretation alone is currently an unacceptablestandard
for LCA and cannot be included. A reasonable period
for malignant transformation remains speculative. Ex-
trapolation from the adenoma-carcinoma sequence of
gut malignancies (in which the epthelial turnover rate
far exceeds thatof liver cells) suggests that at least
three to five years minimum is a reasonable duration,
though longer periods would even be more convincing.
Thirdly, imaging of malignant tumors much arise
within the same focus ofthe liver. Simple convergenceof
abutting tumors must be excluded.
This study of Foster and Berman does have several
limitations however. First, the total number ofpatients
studied was small (39 patients). Although the expected
frequency ofmalignant transformation should be pro-
portionally expressed in this small population, the
chances of observing this event are small. Thus, the
sample size has a real chance of a type II statistical
error. Second, the duration and type offollow-up after
diagnosis ofLCA was uncontrolled. Although 9 of 12
patients of Foster and Berman’s personal series had
follow-up for more than 10 years, the duration of fol-
low-up ofthe 26 patients collected from the literature is
unstated, and is neither as long or as complete as Fos-
ter and Berman’s personal series. Given the timeframe
required to convincingly confirm the adenoma-carci-
noma transformation in the colon, the timeframe
herein may simply be inadequate to observe the trans-
formation ofLCA to HCC. Finally, few ifany reported
biopsies ofobserved LCAs were reported. The natural
history of small HCC itself is only beginning to be
clarified and our knowledge of LCAs is even more
primitive. Could some malignant transformations
have been missed? Did transformation occur in some
patients without clinical recognition?Do HCCs arsing
from LCAs have the same prognosis as HCCs arising
in cirrhotic liver, non-cirrhotic livers, or do they mimic
less agressive HCCs such as fibrolamellar variants?
Was the risk of malignancy reduced in some patients
because ofpartial resection?
Rightfully, Foster and Berman relate their findings
to the clinical management of patients with asympto-
matic LCAs. Albeit rare, they believe that malignant
transformation does occur. Long-term follow-up is the
minimum responsiblemanagement course formost pa-
tients. Neither levels oftumor markers nor discontinu-
ation of sex steroids aborts the risk of malignant
transformation. Importantly, because operative risk
for hepatic resections continues to decline, and, infact,
because the mortality rate for resection for benign dis-
ease is less than the risk of malignant transformation
resection has been advocated for most LCAs, Moreo-
ver, given the age of most patients with LCAs, both
duration and intensity of follow-up will be costly. Al-
though a cost benefit analysis was not addressed by
Foster and Berman, an argument could be made that
immediate operation versus the continual escalating
cost of repeated liver imaging, serial tumor markers,
physical examinations, and health care expense forHPB INTERNATIONAL 61
any patients developing HCC over the course of at
least several decades would be more cost effective.
In conclusion, the article is humbling. In theirovertly
honest and unpretentious evaluation ofthemeagerclini-
cal data available regarding the malignant transforma-
tion of LCAs, Foster and Berman clearly confront us
with our limited knowledge ofLCAs. Despite the pau-
city ofdata, they have proposed tentative management
guidelines which are reasonable with the proviso thatthe
benefit-risk ratio of operation to observation is over-
whelmingly patient favorable. Perhaps our response in
appreciation to these authors should be the establish-
ment of a world-wide registry of patients with histo-
logically-proven LCAs to determine their course; only
collectively will we answer the questions which they so
humbly pose.
David M Nagorney
Department ofSurgery
Mayo Clinic
200 First Street Southwest
Rochester
Minnesota 55905
United States ofAmerica
TYPE IVA CHOLEDOCHAL CYST:
IS HEPATIC RESECTION NECESSARY?
ABSTRACT
Chijiiwa, K., Komura, M. and Kameoka, N. (1994) Postoperativefollowup ofpatients
with type IVA choledochal cysts after excision of extrahepatic cyst. Journal of The
American College of Surgeons; 179." 641-645.
Background: This study concerns patients who have choledochal cyst with intrahepatic
and extrahepatic involvement (type IVA cyst). The extent of excision and the necessity
of hepatectomy, including the intrahepatic cyst in these patients have not been clarified.
Study design: We have performed excision of the extrahepatic cyst with
hepaticojejunostomy upon 13 patients with type IVA cyst during a 16 year period. The
present study was done to examine the size of the anastomotic opening by direct
cholangiography two weeks postoperatively. The long-term results were assessed to
find the appropriate operative management for patients with type IVA cysts.
Results: Intrahepatic cysts were present in both hepatic lobes in 11 patients
(85 percent). None of the patients had carcinoma after excision of extrahepatic cyst
during the follow-up period, which ranged from two months to 16 years. Postoperative
late complications occurred in three patients (23 percent), hepatolithiasis in two and
cholangitis in one. The anastomotic opening of hepaticojejunostomy was 13.3+4.5 mm
in diameter two weeks postoperatively, which was not significantly different when
compared with that in ten patients without late complications (13.4+4.9 mm). The late
complications were successfully treated with either antibiotics or percutaneous
transhepatic cholangiosc0py, and none required a reoperation.
Conclusions: The results suggest that additional hepatectomy is not required because
carcinoma has rarely occurred from the intrahepatic cyst. Excision of an extrahepatic
cyst with a wide hepaticojejunostomy is an acceptable operative management for
patients with type IVA cysts. J. Am. Coll. Surg., 1994, 179: 641-645.
KEY WORDS: Choledochal cyst hepatic resection.